University Research Lecturer
I am a Kidney Research UK Senior Fellow and group co-leader in the Transplantation Research Immunology Group (TRIG).
My research focuses on understanding the mechanisms of immunological tolerance versus immune activation with a view to developing therapies that could benefit transplant recipients and patients with immune related diseases. I am particularly interested in immune cells with regulatory properties, regulatory T cells (Treg) and myeloid-derived suppressor cells and the mechanisms of suppression utilized by these cells. By providing the data on the in vivo efficacy of ex vivo expanded human Treg, my research helped to inform the current clinical study; the TWO Study, in which we are testing safety and efficacy of Treg cells in kidney transplant recipients.
Though my collaborations with colleagues in Oxford and beyond, I am also involved in projects investigating the effectiveness of cancer immunotherapy and changes in the immune response in cancer, both in animal models and clinical trials.
CD70 expression determines the therapeutic efficacy of expanded human regulatory T cells.
Arroyo Hornero R. et al, (2020), Commun Biol, 3
Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials.
Sawitzki B. et al, (2020), Lancet, 395, 1627 - 1639
The ONE Study: Evaluation of Regulatory Cell Therapy in Kidney Transplantation Using a Harmonized Trial Design
HESTER J. et al, (2020), The Lancet
Humanization of Immunodeficient Animals for the Modeling of Transplantation, Graft Versus Host Disease and Regenerative Medicine.
Adigbli G. et al, (2020), Transplantation
Systemic silencing of PHD2 causes reversible immune regulatory dysfunction.
Yamamoto A. et al, (2019), J Clin Invest, 130